The Force Holding the Market Together
The dominant story in equities right now is not interest rates, not oil, and not even the threat of stagflation. It is capital expenditure. With crude over $100 a barrel and bond yields whispering about stagflation as a real possibility, you would expect skittishness across risk assets. Instead, markets are almost unbothered. The reason is simple: the AI CapEx spigot is wide open, and as long as it stays that way, very little else seems to matter to investors.
That makes CapEx the single most important variable to watch. If the spending continues, the rally has fuel. If it stalls, the entire framework holding up valuations has to be rebuilt. And while it is not a base case, the stagflation risk cannot be dismissed. Whatever the Fed says publicly about inflation deserves a healthy dose of skepticism. The bond market is the more honest signal — if yields start to spike, that is the bond crowd telling you something, and it has to live in the back of any serious investor's head.
The Mag 7: Must-Own, but Not Where the Alpha Lives
The Magnificent Seven are still must-own names. They form the spine of any equity portfolio with exposure to the AI buildout. But owning them is not where the real outperformance comes from anymore. The alpha sits at the bottlenecks — the choke points in the supply chain that have to widen if the CapEx is going to keep flowing and AI is going to keep building.
That reframing changes how you read the Mag 7's earnings season. The numbers themselves matter, but the more valuable signal is what each report reveals about what is hard to get, what is constrained, and where the next squeeze will appear.
Apple: A Blowout, and a Tell on Memory
Apple's most recent quarter was, by any reasonable measure, insane — blowouts across the board. Yet the more important takeaway is not the headline beat. Apple used to be the stock you could simply buy and call it a day. That era is over. The ball has moved into many different corners of the market, and Apple, while still a must-own, is no longer the singular vehicle it once was.
What Apple's report actually signaled is that memory is a bottleneck. That is the kind of detail that matters more than the surface results, because it points investors toward where capacity, pricing power, and scarcity are going to drive returns. Memory is rapidly becoming one of the most interesting sub-themes in the AI complex, and it deserves dedicated exposure rather than indirect coverage through the platform names.
Tesla: Stop Pricing It as a Car Company
Treat Tesla as an EV manufacturer and the math falls apart — by that lens it is wildly overvalued. The right framing is that Tesla sits at the leading edge of a number of AI technologies, with self-driving and robotics being the more compelling stories. Add a celebrity CEO whose track record makes betting against him a losing trade, and the case becomes a lot more durable than the auto-industry comps suggest. Rumors that Tesla could eventually be folded into SpaceX are worth tracking, because that kind of structural move would crystallize the AI-and-frontier-tech identity that the market is slowly waking up to.
Meta: The Vulnerable One, but Don't Bet Against Zuckerberg
Among the Mag 7, Meta is the most obvious candidate for further weakness. But picking Meta as a short setup is its own form of overconfidence. Mark Zuckerberg is another operator with a long history of confounding skeptics, and the stock should be expected to come back. The broader principle here is that dips in individual Mag 7 names — and especially the kind of complex-wide drawdown that hit a few weeks ago — are gifts to be bought. The group as a whole has retraced those losses and then some, which is exactly the pattern you want to keep exploiting.
Where the Ball Has Moved: Sneaky AI Plays
Owning the Mag 7 is the table stakes. The interesting opportunities are in names that either sit on critical bottlenecks or have been overlooked because their AI exposure is not obvious.
Tempus AI: The Biotech Edge of AI
The next major AI hotspot is going to be in biotech. Both Jensen Huang and Marc Andreessen have repeatedly singled out healthcare and biotech as the areas where AI will have the most transformative impact. Tempus AI is the leader in that emerging space and is the name to own for that thesis. Its underperformance against the S&P 500 over the past year is precisely what makes it interesting now — the setup looks ripe for a breakout as capital rotates toward AI applications in drug discovery, diagnostics, and clinical decision-making.
Cleveland-Cliffs: The Intel Model of Left-for-Dead AI Plays
There is a powerful pattern emerging where stocks that were written off entirely are getting re-rated as AI infrastructure plays. Call it the Intel model: legacy industrials suddenly finding themselves on the critical path of the buildout. Cleveland-Cliffs fits this archetype neatly. It is the only US steelmaker that produces the grade of steel needed for the kind of towers that the Trump administration has said must be built in large quantities under the recent defense act. That makes it a direct beneficiary of state-driven infrastructure demand tied to national security and AI-adjacent capacity. It does not look like an AI stock at first glance, which is exactly why it is interesting — the market has not fully priced in the dependency.
Putting It Together
The investment frame for this market comes down to a few simple principles. Own the Mag 7 because you have to, but do not expect them to deliver the outsized gains. Track CapEx flows ruthlessly, since that is the keystone holding the entire rally in place. Keep the stagflation risk parked in the back of your mind, and let the bond market tell you when to act on it. And spend most of your effort hunting at the bottlenecks — memory, AI in biotech, and the unloved industrials whose products turn out to be indispensable to the buildout. That is where the real alpha is hiding while everyone else is staring at the same seven tickers.